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The role of daily dialysis in the control of hyperphosphatemia.
In patients with end-stage renal disease (ESRD), hyperphos-
phatemia occurs in the vast majority of patients. The numerous
clinical sequelae of hyperphosphatemia include secondary hy-
perparathyroidism and increased risk of cardiovascular death.
Chronic hemodialysis as it is currently practiced in the United
States does not remove sufficient phosphate to control serum
levels within accepted guidelines. The inadequacy of conven-
tional hemodialysis in removing phosphate mandates the use of
phosphate binders in virtually all hemodialysis patients. Despite
their proven efficacy, these medications fail to control phos-
phorous in 70% of hemodialysis patients. Additionally, these
medications may have untoward side effects that must be con-
sidered since they are typically intended for lifetime use. Quo-
tidian hemodialysis has in previous uncontrolled studies shown
promise in reducing serum phosphorus while at the same time
reducing or eliminating the need for phosphate binders. Recent
results from our group demonstrate for the first time in a con-
trolled fashion the efficacy of short daily dialysis in controlling
serum phosphorus.
Cardiovascular disease is present in end-stage renal
disease (ESRD) patients at rates 10 to 20 times higher
than in the general population, and accounts for 50% of
deaths among ESRD patients [1, 2]. Hyperphosphatemia
is an emerging risk factor for cardiovascular mortality in
the ESRD population [2]. The pathogenesis of cardiac
disease in the ESRD population is complex but involves
the interplay of traditional risk factors along with risk
factors that are specific to the dialysis population. The
novel risk factors among dialysis patients include hyper-
phosphatemia, elevated calcium × phosphorus (Ca × P)
product, lipoprotein (a), hyperhomocysteinemia, chronic
inflammation, and left ventricular hypertrophy [2–8]. Re-
cently, in a rodent model, hyperphosphatemia has been
shown to induce myocardial hypertrophy independent
of effects on hyperparathyroidism or cardiovascular cal-
cification [9]. Thus, hyperphosphatemia must be viewed
in the broad context of a cardiovascular risk factor in
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addition to its role in initiating secondary hyperparathy-
roidism.
Conventional hemodialysis does not remove suffi-
cient phosphate to maintain phosphorus balance in the
vast majority of hemodialysis patients [2, 10]. A 4-hour
hemodialysis session will clear 34 mmol of phosphate
(1054 mg of phosphorus) [11, 12], which is not sufficient to
keep up with the typical phosphorus intake of 800 to 2000
mg per day (equivalent to 25.8–64.5 mmol of phosphate)
in the Western diet. Attempts to enhance phosphate
removal through alterations in dialysate composition
and dialysis membranes have been largely unsuccessful
[13, 14].
The inability of hemodialysis to adequately remove
phosphorus is mainly due to the inaccessibility of phos-
phate during the treatment. Phosphate exists mainly
in the intracellular compartment. During a hemodial-
ysis session with either a high-flux or low-flux dia-
lyzer, serum phosphorus decreases rapidly, reaching a
hypophosphatemic nadir at about 120 minutes [12, 15].
There is an immediate postdialysis rebound in which the
serum phosphorus level can even exceed the predialysis
value [12, 13, 15, 16]. Phosphate efflux into the dialysate
is greatest during the first hour of the treatment, corre-
sponding to the time during which serum phosphorus lev-
els are highest [12]. Phosphate efflux then falls off, but
remains at roughly half the initial value at the end of
the treatment despite a stable serum phosphorus levels
(Fig. 1A). As noted by previous investigators [12, 15, 17–
19], these kinetics suggest a 2-phase model of phosphorus
removal, the first entailing removal of phosphate from the
extracellular fluid compartment, followed by continued
dialysis clearance of phosphorus as phosphate is mobi-
lized from a second (intracellular) pool which maintains
serum phosphorus levels (Fig. 1B).
Thus, the limiting factor in phosphate removal is not
the phosphate flux across the dialyzer [14, 15], but 2 other
main factors. The first is the rapidity of phosphate removal
during the first phase, or early part of the hemodialysis
treatment and the second is the rapidity of intracellular
phosphate mobilization during the second phase. The de-
terminant of phosphate removal during this first phase is
the serum phosphorus level; this is in fact the most impor-
tant clinical factor affecting phosphate removal during
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Fig. 1. (A) Phosphate removal during hemodialysis is greatest in the
first hours of the treatment. Data are taken from Hou et al [13]. The
hourly phosphate removal obtained in this study is plotted versus time.
Dialysis prescription: Qb = 300, Qd = 500 mL/min; dialysate concen-
trations (mmol/L): sodium 140; calcium 1.25; potassium 2; bicarbonate
35; dextrose 11.1. (B) Phosphate removal during hemodialysis involves
2 phases. The figure depicts 2 phases of phosphate removal. At the start
of the treatment, the rate limiting step is the rapidity of phosphate re-
moval from the extracellular fluid, as depicted by the large arrow. The
second phase occurs when the serum phosphorus level has reached a
nadir, and the removal is limited by phosphate mobilization from the
tissues.
hemodialysis [13]. Higher serum phosphorus levels allow
great phosphate removal during each treatment. Surface
area of the dialyzer is also important with larger surface
areas removing more, but the flux of the dialyzer is not im-
portant [14, 15]. The determinant of phosphate removal
during the second phase of hemodialysis is the rapidity
of phosphate mobilization from body pools (Fig. 1A).
It has been shown that hemodiafiltration can increase
phosphate mobilization from the tissues by increasing the
postdialytic phosphate rebound [16]. Thus, hemodiafiltra-
tion acutely increases predialytic phosphorus levels, but
over 3 months decreases serum phosphorus [16]. The pro-
posed mechanism for the increased phosphate removal
is the convective removal of this solute during hemodi-
afiltration [16–19]. Unfortunately, hemodiafiltration is a
modality not readily available to ESRD patients in the
United States.
Since conventional 3 times per week hemodialysis is
inadequate to maintain phosphate balance at acceptable
serum levels of phosphorus, the use of phosphate binders
is mandatory to minimize phosphorus absorption from
the diet. Currently, 2 options exist in the United States to
bind intestinal phosphate on a chronic, long-term basis:
calcium-based binders and sevelamer. Calcium acetate
and calcium carbonate are effective in reducing serum
phosphorus levels in hemodialysis patients, and in reduc-
ing secondary hyperparathyroidism [20]. However, con-
cerns have been raised about the safety of the long-term
use of calcium-based binders because of the potential for
the chronic calcium load to induce cardiovascular calci-
fication, especially in the context of the use of vitamin
D analogues [21, 22]. Sevelamer hydrochloride, a quater-
nary amine anion exchange resin that binds phosphate
ions and releases hydrochloric acid, is an alternative phos-
phate binder that is neither aluminum nor calcium based
[23]. This agent is also effective in reducing phosphorus
and reducing hyperparathyroidism, and does not expose
the patient to a calcium load. Because of its mechanism of
action, sevelamer can lead to an acid load, and in animal
studies has been associated with acidosis [24]. Nonethe-
less, despite use of these phosphate binders, dietary phos-
phorus restriction, and conventional hemodialysis, 70%
of patients on hemodialysis fail to achieve goals for serum
phosphorus and Ca × P product recommended in the
K/DOQI guidelines [2, 10].
In order to control serum phosphorus more effectively
in our ESRD population as a whole, dialytic removal
of phosphorus must be improved. Given the kinetics of
phosphate removal during dialysis, it is clear that the time
of dialysis must be increased in order to achieve bet-
ter phosphate removal with hemodialysis. The HEMO
study demonstrated that increased dose of dialysis, with-
out much increase in time of dialysis, did not favorably af-
fect mortality [25]. Despite these findings, several groups
have found beneficial effects on cardiovascular risk fac-
tors: blood pressure control, improved anemia by reduc-
ing erythropoietin requirements, and regression of left
ventricular hypertrophy [26–30] with the use of quotid-
ian dialysis. Additionally, control of serum phosphorus
is reportedly improved with the use of either daily or
nocturnal dialysis [30–34]. In our study, instead of di-
viding the 12-hour weekly time over 6 2-hour sessions,
we increased both the total time and the frequency of
hemodialysis (6 times per week for 3 hours) in order to
maximize phosphate removal [35]. Assuming a low phos-
phorus intake of 900 mg per day of phosphorus (equiva-
lent to 29 mmol of phosphate), and phosphorus kinetics
shown in Figure 1A, conventional hemodialysis is woe-
fully inadequate at achieving phosphorus balance, while
short daily hemodialysis comes much closer to this goal
without the use of phosphate binders (Fig. 2A and B).
There are only 4 studies of quotidian dialysis that ad-
dress the issue of phosphorus control, and none of these
studies is controlled [31–34]. The summary of our re-
view of the literature is presented (Table 1). A universal
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Fig. 2. (A) Conventional hemodialysis alone
leads to significantly positive phosphorus bal-
ance. Using the phosphate removal from a 4-
hour hemodialysis treatment (shown in Figure
1A), and assuming a phosphorus intake of 900
mg (equivalent to 29 mmol of phosphate), the
predicted phosphate balance using conven-
tional hemodialysis over the week is shown.
(B) Short daily hemodialysis alone is close to
achieving phosphate balance. Using the phos-
phate removal from a 3-hour hemodialysis
treatment (shown in Figure 1A), and assum-
ing a phosphorus intake of 900 mg (equivalent
to 29 mmol of phosphate), the predicted phos-
phate balance using short daily hemodialysis
over the week is shown.
Table 1. Summary of daily dialysis studies
No. of
Author (ref) subjects Dialysis modality Prescription/(duration) Phosphorus control Other factors
Kooistra [18] 13 Daily home hemodialysis 6 times weekly (6 months) Decrease dose of P binders Decreased blood pressure in
hypertensive patients
Uldall [17] 5 Nocturnal hemodialysis 5–7 nights/wk, 8 hrs/night,
(6–16 months)
Discontinue P binder use Increased dietary protein
intake
Mucsi [20] 7 Nocturnal hemodialysis 6 nights/wk, 8 hrs/night, (5
months)
Discontinue P binder use Increased dietary protein
intake
Lindsay [21] 12 Nocturnal hemodialysis 5–6 nights/wk, 6–8 hrs/night,
(5–36 months)
Decreased use of P binder,
Decreased Ca × P product
Improved blood pressure
control, Improved QOL
11 Short daily hemodialysis 5–6 days/wk, 1.5–2.5 hrs/day,
(5–36 months)
Decreased Ca × P product Improved blood pressure
control, Improved QOL
Mizani [23] 51 Conventional hemodialysis 3 days/wk, 4 hrs/day (1 year) No change in phosphorus,
continued use of phosphate
binders
Decreased iPTH
26 Short daily hemodialysis 6 days/wk, 3 hrs/day (1 year) Decreased serum phosphorus,
73% patients discontinue
the use of phosphate binders
at 12 months
Decreased iPTH
finding in these studies is either a decrease in require-
ment for phosphate binders or complete cessation of
these agents [31–34]. Additionally, concurrent increases
in protein intake have been reported in 2 of these studies
[31, 33]. Lindsay et al reported a significant decrease in
Ca × P product using a short daily hemodialysis regimen
(1.5–2.5 hours a day, 6 days a week), and using nocturnal
hemodialysis [34]. In the nocturnal hemodialysis group
this was achieved with a reduction in the use of phos-
phate binders [34].
Our study is the first to assess, in a large group of pa-
tients, the efficacy of short daily hemodialysis in reducing
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Table 2. The San Antonio Prospective Study on daily dialysis
Baseline 6 months 12 months
Conventional hemodialysis (N = 51)
Ca mg/dL 9.0 ± 0.70 8.8 ± 0.55 8.9 ± 0.65
P mg/dL 5.0 ± 1.49 4.9 ± 1.12 5.1 ± 1.14
iPTH pg/mL 717 ± 361 255 ± 182 428 ± 312a
Short daily hemodialysis (N = 26)
Ca mg/dL 8.4 ± 1.26 9.0 ± 0.66 8.9 ± 0.74a
P mg/dL 6.3 ± 2.57 4.6 ± 1.06 4.0 ± 1.19a
iPTH pg/mL 690 ± 596 337 ± 255 312 ± 193a
Adapted from Mizani and Ayus [35]. Seventy-three percent of SDHD patients
discontinued phosphate binders at 12 months.
aP < 0.05 vs. baseline.
serum phosphorus in a controlled manner [35]. Our study
employed a protocol that called for 3 hours of hemodial-
ysis 6 times per week. The conventional hemodialysis
group was treated for 4 hours 3 times per week. In addi-
tion to delivering a 60% greater weekly Kt/V, this short
daily hemodialysis (SDHD) regimen maximizes phos-
phate removal by increasing the total dialysis time. In
our study, 77 hemodialysis patients matched for age, sex,
and comorbidities were treated with either conventional
thrice-weekly dialysis (N = 51), or were treated with
short daily hemodialysis (N = 26). Table 2 summarizes
the observations from this study. A significant reduction
in PTH levels of 55% and 40% was seen in the SDHD
and conventional dialysis groups, respectively. A signif-
icant decrease in serum phosphorus levels was seen in
the patient group treated with SDHD (6.3 ± 2.57 mg/dL
at baseline, 4.61 ± 0.6 mg/dL at 6 months of treatment,
and 4.0 ± 1.19 mg/dL at 12 months of dialysis treatment,
P < 0.004) that was not seen in the patients on conven-
tional hemodialysis. This statistically significant reduction
in serum phosphorus occurred despite the withdrawal of
phosphate binders in 73% of the SDHD group, while the
phosphate binder requirements were unchanged in the
control group. To our knowledge, this is the first con-
trolled study to demonstrate effective control of serum
phosphorus level using short daily hemodialysis in a large
group of patients with ESRD.
CONCLUSION
Uncontrolled hyperphosphatemia is a serious short-
coming in the delivery of hemodialysis in the United
States. In addition to exposing patients to the morbid-
ity of secondary hyperparathyroidism, it is increasingly
clear that hyperphosphatemia is a serious cardiac risk
factor [2]. Conventional hemodialysis does not remove
adequate phosphorus to maintain phosphorus balance
without the use phosphate binders. Even the addition
of these medications is not sufficient to attain KDOQI
guidelines for control of phosphorus and Ca × P product
in the majority of patients, and all phosphate binders have
potential side effects which must be considered. Previous
investigators have shown that daily hemodialysis is effica-
cious in controlling serum phosphorus [31–34]. Our group
has shown for the first time in a large group of patients,
in a controlled manner, that short daily hemodialysis can
control hyperphosphatemia while nearly eliminating the
need for phosphate binders [35]. In our opinion, daily
hemodialysis is the best treatment to control hyperphos-
phatemia and ameliorate both the metabolic and cardio-
vascular complications of this disorder.
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